Washington State University, College of Pharmacy/Providence Visiting Nurses Association, Spokane, WA 99202, United States.
Maturitas. 2011 Jun;69(2):113-9. doi: 10.1016/j.maturitas.2011.03.009. Epub 2011 Apr 9.
Osteoporosis is a common condition associated with aging but has been considered to primarily affect women because of the substantial effect of menopause on osteoporosis. Bone density can decrease with aging in men but occurs more gradually than in postmenopausal women. With improvements in healthcare and extended life expectancy, it is becoming more apparent that osteoporosis affects men and can have serious consequences. Recently, a greater number of osteoporosis studies are either including men or focusing specifically on them. The majority of medication trials in men, however, used bone density as the primary outcome rather than fractures. Therefore, treatment data for men is still rather limited, and there is also very little information in the oldest subset of this population. The more recent guidelines for treating osteoporosis now include men, but the recommendations for screening and treatment are not necessarily gender specific. Despite the limited data, some osteoporosis treatments have received approval to treat or prevent osteoporosis specifically in men. Future studies must provide greater information on fracture prevention in men and also must include a greater population of the oldest geriatric patients, who are typically not well represented in osteoporosis trials, to evaluate any differences in both efficacy and side effects. The oldest group is important because they are at the highest risk for both osteoporosis-related complications and treatment-related adverse events.
骨质疏松症是一种与衰老相关的常见病症,但由于绝经对骨质疏松症的重大影响,它主要被认为会影响女性。男性的骨密度会随着年龄的增长而下降,但比绝经后女性的下降速度要慢。随着医疗保健的改善和预期寿命的延长,越来越明显的是,骨质疏松症也会影响男性,并可能产生严重后果。最近,越来越多的骨质疏松症研究要么纳入男性,要么专门针对男性。然而,男性的大多数药物试验都将骨密度作为主要结果,而不是骨折。因此,男性的治疗数据仍然相当有限,而且在这个人群中最年长的一部分也几乎没有信息。现在,治疗骨质疏松症的最新指南包括了男性,但筛查和治疗的建议不一定具有性别特异性。尽管数据有限,但一些骨质疏松症治疗方法已被批准专门用于治疗或预防男性骨质疏松症。未来的研究必须提供更多关于男性骨折预防的信息,并且还必须包括更大多数最年长的老年患者,他们在骨质疏松症试验中通常代表性不足,以评估在疗效和副作用方面的任何差异。最年长的一组很重要,因为他们面临与骨质疏松症相关的并发症和治疗相关的不良事件的风险最高。